OnabotulinumtoxinA is an established treatment for glabellar frown lines, but its effects on lines at repose are less well documented.
To assess the effect of onabotulinumtoxinA on elimination of mild lines at repose.
Data from two randomized, double-blind, placebo-controlled studies were included. Elimination of mild lines at repose was defined as change from mild to none on the Facial Wrinkle Scale.
Analysis included 183 participants who received 20 U of onabotulinumtoxinA and 64 participants who received placebo, all with mild lines at repose at baseline. Participants were evaluated 7, 30, 60, 90, and 120 days posttreatment. Compared to placebo, onabotulinumtoxinA-treated participants were significantly more likely to have their lines at repose eliminated at each study day; [odds ratios ranged from 42.7 (95% confidence interval (CI)=12.9–141.9) at day 30 to 4.9 (95% CI=2.2–10.8) at day 120 (p<.0001 at each day)]. The highest response rate was observed at day 30 (68%).
OnabotulinumtoxinA has demonstrated the ability to eliminate mild glabellar lines at repose for a significant number of patients. This effect, albeit more subtle than the effect on dynamic or more severe glabellar lines, may be an important treatment goal for patients who seek a smoother appearance at repose.
Drs. A. Carruthers and J. Carruthers are investigators and consultants for Allergan. Dr. Brin and Dr. Lei are employed by Allergan and receive direct salary compensation. Dr. Brin, Dr. Lei, and Ms. Eadie hold an equity interest in the companies in the form of stock, stock options, or both. Dr. Pogoda and Ms. Eadie have consulting contracts with Allergan.
1Departments of *Dermatology and Skin Science and †Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC, Canada; ‡Allergan, Inc., Irvine, California; §University of Southern California, Los Angeles, California; ¶Independent contractor, Corvallis, Montana, Minnesota; ∥Department of Neurology, University of California, Irvine, California
Address correspondence and reprint requests to: Mitchell F. Brin, MD, Allergan, Inc., 2525 Dupont Drive, Irvine, CA 92612, or e-mail: firstname.lastname@example.org